Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Hydrocephalus in neuromyelitis optica.
Do Not Miss the Eye in Acute Demyelinating Encephalomyelitis.
An epidemiological study of neuromyelitis optica in Isfahan.
Hepatocyte Growth Factor Limits Autoimmune Neuroinflammation via Glucocorticoid-Induced Leucine Zipper Expression in Dendritic Cells.
Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation?
Voiding dysfunction in patients with neuromyelitis optica spectrum disorders.
Transcriptional de-repression of ERVWE1 following influenza A virus infection.
Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses.
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
A Voxel-based Morphometry Study of Grey Matter Volume Changes in Neuromyelitis Optica Patients.
Managing Disability in Progressive Multiple Sclerosis.
Impaired decision-making and diffusion orientational complexity in people with multiple sclerosis.
Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability.
[Consensus document on spasticity in patients with multiple sclerosis.]
Assessment of trace elements in human brain using inductively coupled plasma mass spectrometry.
Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations.
Neuregulin and BDNF Induce a Switch to NMDA Receptor-Dependent Myelination by Oligodendrocytes.
Demyelinating disease: Is TOPIC the last trial for clinically isolated syndrome?
Remotely-supervised transcranial direct current stimulation (tDCS) for clinical trials: guidelines for technology and protocols.
Efficacy of lower fingolimod doses in the treatment of MS.
Endotoxin-induced systemic inflammation activates microglia: [(11)C]PBR28 positron emission tomography in nonhuman primates.
Telemedicine for Monitoring MS Activity and Progression.
Association between age at onset of multiple sclerosis and vitamin D level-related factors.
Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease.
Natalizumab in the treatment of pediatric multiple sclerosis.

Pages